A total of 132 asymptomatic Western blot (WB)+, 62 EIA+/WB-, and 8 EIA+/WB indeterminate donors have been enrolled in a 5-year prospective study. The source of HIV exposure was homosexual activity, 68% (83% of males); hetero- sexual contact, 28% (96% of females); IV drugs, 3%; transfusion, 2%; unknown, 6%. Compared with the WB- controls, WB+ donors were more frequently black (59 vs 7%), male (82 vs 57%), young (mean age 32 vs 40), first-time donors (26 vs. 7%), and have a history of venereal disease (52 vs. 8%). The ratio of high to low risk WB+ donors decreased from 5:1 to 1:1 during the first 20 months of the study. On initial evaluation, WB+ donors were significantly more likely than WB- - donors to have T4 cells < 400/uL (39 vs 7%) T4/T8 ratio <0.8 (68 vs 3%), IgG >1.8 g/dL (48 vs 2%), and positive anti-HBc (55 vs 2%). Diminished responses to tetanus, PWM, and PHA were seen in 46, 38, and 18% of WB+, vs 7, 18, and 4% of WB- donors. By 1 yr of follow-up, 11% of WB+ individuals had abnormal responses to all 3 mitogens; by 18 mos, 16% had T4 <100/uL and 20% had T4/T8 <0.2. HIV was isolated from 32 of 98 (33%) WB+ donors on at least one visit. Fifty-eight percent of WB+ donors were initially in CDC group II; 22 of 66 (33%) of these subsequently developed lymphadenopathy. Fifteen of 132 (11%) progressed to CDC IV; 5 developed thrush, 5 pneumocystis, 1 tuberculosis, and 4 constitutional disease. None of 70 EIA+/WB- or indeterminate donors were in HIV risk groups and none had evidence of HIV-related immune dysfunction or positive viral cultures.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL002040-06
Application #
3874305
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code